Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study.
Juárez A, Salas MQ, Pedraza A, Suárez-Lledó M, Rodríguez-Lobato LG, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Charry P, Arcarons J, Llobet N, Rosiñol L, Fernández-Avilés F, Rovira M, Martínez C. Juárez A, et al. Among authors: llobet n. Cancers (Basel). 2024 Jul 17;16(14):2567. doi: 10.3390/cancers16142567. Cancers (Basel). 2024. PMID: 39061206 Free PMC article.
High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A, Jorge S, Suárez-Lledó M, Pereira A, Gutiérrez-García G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C. Pedraza A, et al. Among authors: llobet n. Transplant Cell Ther. 2021 Jul;27(7):619.e1-619.e8. doi: 10.1016/j.jtct.2021.03.022. Epub 2021 Mar 25. Transplant Cell Ther. 2021. PMID: 33895157 Free article.
Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide.
Marco DN, Salas MQ, Gutiérrez-García G, Monge I, Riu G, Carcelero E, Roma JR, Llobet N, Arcarons J, Suárez-Lledó M, Martínez N, Pedraza A, Domenech A, Rosiñol L, Fernández-Avilés F, Urbano-Ispízua Á, Rovira M, Brunet M, Martínez C. Marco DN, et al. Among authors: llobet n. Pharmaceuticals (Basel). 2022 Dec 9;15(12):1529. doi: 10.3390/ph15121529. Pharmaceuticals (Basel). 2022. PMID: 36558980 Free PMC article.
Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS, Suárez-Lledó M, Pereira A, Gutierrez G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C. Jorge AS, et al. Among authors: llobet n. Biol Blood Marrow Transplant. 2018 Jun;24(6):1196-1202. doi: 10.1016/j.bbmt.2018.01.021. Epub 2018 Feb 2. Biol Blood Marrow Transplant. 2018. PMID: 29410343 Free article.
Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation.
Marco DN, Molina M, Guio AM, Julian J, Fortuna V, Fabregat-Zaragoza VL, Salas MQ, Monge-Escartín I, Riu-Viladoms G, Carcelero E, Roma JR, Llobet N, Arcarons J, Suárez-Lledó M, Rosiñol L, Fernández-Avilés F, Rovira M, Brunet M, Martínez C. Marco DN, et al. Among authors: llobet n. Pharmaceuticals (Basel). 2024 Apr 25;17(5):553. doi: 10.3390/ph17050553. Pharmaceuticals (Basel). 2024. PMID: 38794124 Free PMC article.
Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation.
Suárez-Lledó M, Marcos MÁ, Cuatrecasas M, Bombi JA, Fernández-Avilés F, Magnano L, Martínez-Cibrián N, Llobet N, Rosiñol L, Gutiérrez-García G, Jorge S, Martínez C, Rovira M, Urbano-Ispizua Á. Suárez-Lledó M, et al. Among authors: llobet n. Biol Blood Marrow Transplant. 2019 Nov;25(11):2281-2286. doi: 10.1016/j.bbmt.2019.07.016. Epub 2019 Jul 17. Biol Blood Marrow Transplant. 2019. PMID: 31325586 Free article. Clinical Trial.
Optimized GVHD Prevention in HLA-Mismatched Unrelated Allogeneic HCT Using a PTCY-Based Approach.
Pinto FR, Suárez-Lledó M, Guardia L, Charry P, Cid J, Lozano M, Pedraza A, de Llobet N, Corrius G, Moreno C, Esteve J, Serra C, Carreras E, Rosiñol L, Fernández-Avilés F, Rovira M, Martinez C, Salas MQ. Pinto FR, et al. Among authors: de llobet n. Eur J Haematol. 2024 Dec 30. doi: 10.1111/ejh.14378. Online ahead of print. Eur J Haematol. 2024. PMID: 39739412
Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Salas MQ, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LG, Brusosa M, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Arcarons J, de Llobet N, Rosiñol L, Esteve J, Urbano-Ispizua Á, Carreras E, Fernández-Avilés F, Rovira M, Martinez C. Salas MQ, et al. Among authors: de llobet n. Transplant Cell Ther. 2024 Feb;30(2):213.e1-213.e12. doi: 10.1016/j.jtct.2023.11.020. Epub 2023 Nov 30. Transplant Cell Ther. 2024. PMID: 38042256
Rationale and design of the colchicine for the prevention of perioperative atrial fibrillation in patients undergoing major noncardiac thoracic surgery (COP-AF) trial.
Conen D, Popova E, Wang MK, Chan MTV, Landoni G, Reimer C, Srinathan SK, Cata JP, McLean SR, Trujillo Reyes JC, Grande AM, Gonzalez Tallada A, Sessler DI, Fleischmann E, Maziak DE, Kabon B, Voltolini L, Gutiérrez-Soriano L, Tandon V, DuMerton D, Kidane B, Rajaram R, Shargall Y, Neary JD, Wells JR, McIntyre WF, Blum S, Ofori SN, Vincent J, Xu L, Li Z, Healey JS, Garg AX, Devereaux PJ; COP-AF Investigators. Conen D, et al. Am Heart J. 2023 May;259:87-96. doi: 10.1016/j.ahj.2023.01.018. Epub 2023 Feb 7. Am Heart J. 2023. PMID: 36754105 Clinical Trial.
Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Pedraza A, Salas MQ, Rodríguez-Lobato LG, Charry P, Suárez-Lledo M, Martínez-Cibrian N, Doménech A, Solano MT, Arcarons J, de Llobet N, Rosiñol L, Gutiérrez-García G, Avilés FF, Urbano-Ispízua Á, Rovira M, Martínez C. Pedraza A, et al. Among authors: de llobet n. Transplant Cell Ther. 2023 Mar;29(3):181.e1-181.e10. doi: 10.1016/j.jtct.2022.12.005. Epub 2022 Dec 14. Transplant Cell Ther. 2023. PMID: 36526259 Free article.
16 results